Identification and expansion of human colon-cancer-initiating cells

By L. Ricci-Vitiani, D. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, R. Maria. Nature, 2007

4,187 citations recorded by the source corpus.

Subfields: Biotechnology, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/22f4c7bf7fc9f16f0cacfaaa4437a4abc8316fec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. R. Weinberg
2. Jane E. Visvader
3. K. Polyak
4. R. Hill
5. Jing Yang
6. D. Hanahan
7. Lisa M. Coussens

In Genetics

1. R. Weinberg
2. Arne Traulsen
3. Martin A. Nowak
4. Jing Yang
5. S. Baylin
6. Eric R. Fearon
7. Niko Beerenwinkel
8. William C. Hahn

In Oncology

1. R. Weinberg
2. K. Polyak
3. Jane E. Visvader
4. J. Dick
5. Antonija Krešo
6. S. Morrison
7. J. Medema
8. Jing Yang

Citations in the corpus

• Exploring the role of cancer stem cells in radioresistance (2008, background): “These data suggest that phenotypically distinct tumorigenic populations exist inside a tumou”
• Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. (2009, background): “In colorectal cancer, CD133 positive cells have been shown to have cancer stem cell characteristics [60].”
• Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013, background): “Cancer stem cells have also been isolated from medulloblastoma, glioblastoma [41], ependymoma [42], colon cancer [43,44], chronic and acute myeloid leukemia [45], pancreatic cancer [46], and head and neck squamous cell carcinomas [47].”
• Evolution of the cancer stem cell model. (2014, background): “…including brain (Singh et al., 2004), head and neck (Prince et al., 2007), pancreas (Hermann et al., 2007; Li et al., 2007), lung (Eramo et al., 2008), prostate (Collins et al., 2005; Patrawala et al., 2006), colon (O’Brien et al., 2007; Ricci-Vitiani et al., 2007), and sarcoma (Wu et al., 2007).”
• Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy (2008, background): “Many solid tumor types, including breast cancer, exhibit a functional hierarchy of cancer cells of which only a small subpopulation of replenishing stem-like cells can give rise to the differentiated cells that comprise the bulk tumor [2-6].”
• Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition (2008, background): “Over the past few years, candidate cancer stem cells have been identified in a variety of human malignancies including leukemias and a number of solid tumors such as glioblastomas, medulloblastomas and carcinomas [11–24].”
• CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. (2014, background): “CD44v6 Expression Demarcates a Highly Tumorigenic CR-CSC Population with Metastatic Potential We and others previously demonstrated that CR-CSCs are enriched in tumor spheres or freshly isolated CD133 cells (O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Todaro et al., 2007).”
• CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway (2008, background): “To date, CD133 has also been shown to mark the CSC population in cancers of the brain, prostate, pancreas and colon (Hemmati et al., 2003; Singh et al., 2003; Li et al., 2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007).”
• SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma (2009, background): “, 2004) as well as in colon cancer (O’Brien et al., 2007; Ricci-Vitiani et al., 2007) and prostate cancer (Richardson et al.”